A PET/CT imaging agent for prostate cancer before surgery
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new imaging agent (INR101) used with a PET/CT scan to help see prostate cancer before surgery. The scan may help doctors plan your prostate removal surgery more accurately.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man aged 18 or older.
- Your prostate cancer must be confirmed by a biopsy and be at an intermediate-risk or higher level.
- You plan to have surgery to remove your prostate and nearby lymph nodes.
- Your blood test results (for blood cells, liver, and kidney function) must be within certain limits.
- You must not have had hormone therapy, chemotherapy, or radiation for your prostate cancer before the imaging.
- You must be willing to avoid fathering children and use contraception during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental treatment for advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The treatment is a radioactive drug that targets a protein called PSMA on cancer cells, aiming to deliver radiation directly to the tumor.
This trial tests a new investigational drug called INR102 for prostate cancer that has spread and stopped responding to standard treatments. It's given by injection, and the study will check if it's safe and if it can shrink or slow the cancer.
This trial tests a new imaging drug that may help your doctor see the exact location of prostate cancer using a PET scan. The imaging is done before surgery to remove the prostate or, if you have recurrence, to find where the cancer has returned.
This study compares a new PET/CT imaging agent (61Cu-NU101) with the standard one (Pylarify) to see if it's better at detecting prostate cancer that has spread to a few places. If you have oligometastatic prostate cancer, this trial might help improve how doctors find and monitor your cancer.
This trial tests if a special PET scan using PSMA-1007 can find prostate cancer spread in men who have just been diagnosed with high-risk prostate cancer and plan to have surgery. The scan may help doctors better understand the cancer before removing the prostate and lymph nodes.
This trial tests a special type of scan (99mTc-MIP-1404 SPECT/CT) to see how well it can detect the spread of high-risk prostate cancer. It may help doctors better understand the stage of the disease before deciding on treatment.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.